Medical/Pharmaceuticals
The Registrational Clinical Data of Glecirasib was Published in Nature Medicine
BEIJING, SHANGHAI and BOSTON, Jan. 6, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been publishe...
2025-01-07 08:30
1031
WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager
SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO),today announced an agreement with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focus...
2025-01-07 08:00
1101
VIV™ Ring: The World's 1st Smart Ring with Generative Sleep Aid Sound at CES 2025
* The Intuitive Smart Ring Challenging Oura and Galaxy Ring * Generative Sleep Aid Sound Enhancing Beyond Biometrics Measurement LAS VEGAS ,Jan. 6, 2025 /PRNewswire/ -- VIV Health is thrilled to announce the upcoming launch of the VIV™ Ring, the world's first smart ring equipped with Generative...
2025-01-06 23:30
1309
Datasea Announces Entry into Agreements that Will Place its Acoustic High-Tech Products in a Total of 263 Beauty Stores in Northern China
The New Agreements Projected to Generate Sales of up to 140,000 Units and $11 Million in Revenue by Year End 2025 BEIJING, Jan. 6, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS, "Datasea" or "the Company"), aNevada-based digital technology company specializing in acoustic high-tech and 5G AI m...
2025-01-06 22:45
2848
EMSRUN Medical Celebrates 15 Years of Excellence in Life-Saving Solutions
WUXI, China, Jan. 6, 2025 /PRNewswire/ -- EMSRUN Medical, a leader in tactical, pre-hospital, and civilian emergency medical solutions, marks its 15th anniversary this year. Since its establishment in 2010, the company has built an outstanding reputation for delivering critical solutions to comba...
2025-01-06 22:10
1246
Technoderma Medicines Completes Positive Ph2a Proof- of Concept Trial with Topical TDM-180935 Ointment for Atopic Dermatitis
CHENGDU, China, Jan. 6, 2025 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment in patients with Atopic Dermatitis (AD). Th...
2025-01-06 21:00
1383
Concord Medical Announces Result of 2024 Annual General Meeting
BEIJING, Jan. 6, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it held its 2024 annual general meeting of shar...
2025-01-06 20:30
2416
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
* Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization * The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, anddata is ...
2025-01-06 20:00
914
Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program
SHANGHAI, Jan. 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women's health with significant unmet medical needs, announced the signing of an investigatio...
2025-01-06 18:05
1194
Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization
* Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance * Marks a key step forward for the world's first once-monthly IL-4Rα-targeting antibody therapeutic for Th2-driven diseases, with a strategic focus on entering the Ameri...
2025-01-03 21:15
4144
GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer
SHENZHEN, China, Jan. 3, 2025 /PRNewswire/ -- Shenzhen GRIT Biotechnology Co., Ltd., a leading company in cell therapy globally, today announced the appointment ofJie Jia, Ph.D., as Chief Operating Officer (COO), effective on the date of this press release. Dr. Jia, Jie brings over 20 years of...
2025-01-03 15:30
2419
Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration with BeiGene
CAMBRIDGE, Mass., Jan. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced that BeiGene. Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization right...
2025-01-03 13:30
1731
Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044
WUHAN, China, Jan. 2, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, today announced the first patient dosing inAustralia on Dec 30, 2024 for Phase 1 cl...
2025-01-03 01:43
2026
Fapon Biopharma Introduces FP008 at Biotech Showcase: A Safer and More Effective Immunotherapy for Refractory Cancers
SAN FRANCISCO, Jan. 2, 2025 /PRNewswire/ -- Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, will present its latest breakthrough immunocytokine, FP008, onJan 14, 2025, at the Biotech Showcase investor conference, following J.P. Morgan Healthcare Week. This ...
2025-01-02 17:17
1109
FDA Grants Orphan Drug Designation to MicuRx's MRX-5 for NTM Infections
SHANGHAI, Jan. 1, 2025 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx"，688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment ofnon-tuberculous myco...
2025-01-02 12:52
1824
CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy
SHANGHAI, Dec. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the initiation of an investigator-initiated trial (IIT) inChina for K...
2024-12-31 21:50
2944
Ractigen Therapeutics Founder Dr. Long-Cheng Li Awarded 2024 Life Science Ice Breaking Award
NANTONG and SUZHOU, China, Dec. 31, 2024 /PRNewswire/ -- Ractigen Therapeutics proudly announces that its Founder and CEO, Dr.Long-Cheng Li, has been honored with the 2024 Life Science Ice Breaking Award. This award, established by Mr. Cai Lei, a prominent ALS patient and advocate, along with his ...
2024-12-31 20:00
1972
CG MedTech and CGBIO Showcase Korea's Spine Surgery Excellence to Global Experts
SEOUL, South Korea, Dec. 31, 2024 /PRNewswire/ -- CG MedTech (f/k/a Innosys, CEO Ju Mi Chung), a leading Korean orthopedic implant research and manufacturing company, partnered withCGBIO to host the International Spine Endoscopy Training Course. The event welcomed 12 medical professionals from nin...
2024-12-31 20:00
1781
Ping An Health Supported the Official Release of the "Group Standards for Remote and Internet-Based Family Doctor Healthcare Services"
HONG KONG and SHANGHAI, Dec. 31, 2024 /PRNewswire/ -- With Ping An Healthcare and Technology Company Limited's ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) strategic support, and guidance from the General Practice Development Research Center of Peking Universit...
2024-12-31 15:26
3678
Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene
SOMERSET, N.J., SHANGHAI and SUZHOU, China, Dec. 30, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074 from DualityBio, securing global development, manufacturing, and ...
2024-12-31 08:00
1767
Week's Top Stories
Most Reposted
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
[Picked up by 331 media titles]
2025-01-18 03:30
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 323 media titles]
2025-01-13 09:05
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
[Picked up by 305 media titles]
2025-01-18 17:00
RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility
[Picked up by 295 media titles]
2025-01-14 21:00
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 294 media titles]
2025-01-13 10:44
Most Read
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
2025-01-18 03:30
8158
Boosting Yeast Protein Production to Meet the Growing Global Demand for Alternative Proteins
2025-01-17 22:46
7947
Dongying's vibrant Spring Festival awaits visitors
2025-01-17 21:46
7641